HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D

AIDS

Volumn 17, Issue 4, 2003, Pages 513-520

  Cozzolino, Mario ^a   Vidal, Marcos ^a   Arcidiacono, Maria Vittoria ^a   Tebas, Pablo ^a   Yarasheski, Kevin E ^a   Dusso, Adriana S ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Renal Division Box 8126 ^*  (United States)

Author keywords

Bone mineral metabolism; Cytochrome P450; Protease inhibitors; Vitamin D

Indexed keywords

1 ALPHA HYDROXYLASE; 25 HYDROXYLASE; CALCITRIOL; ENZYME; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; STEROID 24 HYDROXYLASE; UNCLASSIFIED DRUG; VITAMIN D;

ARTICLE; CATABOLISM; CONTROLLED STUDY; DEMINERALIZATION; DOSE RESPONSE; DRUG ACTIVITY; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; LIVER CELL; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; BONE REMODELING; CALCITRIOL; CELL LINE; CYTOCHROME P-450 CYP27A1; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSION, CHEMICAL; HEPATOCYTES; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MACROPHAGES; NELFINAVIR; RITONAVIR; STEROID HYDROXYLASES; VITAMIN D;

EID: 0037423860     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200303070-00006     Document Type: Article

References (37)

1. Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med 1997, 127:948.
2. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy [letter]. Ann Intern Med 1997, 127:947.
3. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. 'Buffalo hump' in men with HIV-1 infection. Lancet 1998, 351:867-870.
4. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 Protease inhibitors. A review for clinicians. JAMA 1997, 277:145-153.
5. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998, 12:1735-1744.
6. Carr A, Samaras K, Chisholm DJ, Cooper DA. Abnormal fat distribution and use of protease inhibitors. Lancet 1998, 351:1736.
7. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-58.
8. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099.
9. Cart A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitorrelated lipodystrophy syndrome. AIDS 2000, 14:F25-F32.
10. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999, 13:F63-70.
11. Henry K, Melroe H, Huebsch J, Balks HJ, Brabant G, Korner T, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998, 351:1328.
12. Yarasheski KE, Tebas P, Sigmund C, Dagogo-Jack S, Bohrer A, Turk J, et al. Insulin resistance in HIV protease inhibitorassociated diabetes. J Acquir Immune Defic Syndr 1999, 21:209-216.
13. Nolan D, Upton R, McKinnon E, John M, James I, Adler B, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001, 15: 1275-1280.
14. Paton NI, Macallan DC, Griffin GE, Pazianas M. Bone mineral density in patients with human immunodeficiency virus infection. Calcif Tissue Int 1997, 61:30-32.
15. McGowan I, Cheng A, Coleman S, Johnson A, Genant H. Assessment of bone mineral density (BMD) in HIV-infected antiretroviral-therapy-nave patients. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 628].
16. Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS 2001, 15:703-709.
17. Holick MF. Vitamin D and bone health. J Nutr 1996, 126:1159S-1164S.
18. Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol 1999, 277:F157-175.
19. 3. J Nutr 1995, 125:1690S-1694S.
20. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998, 38:106-111.
21. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44:190-194.
22. Dusso AS, Kamimura S, Gallieni M, Zhong M, Negrea L, Shapiro S, et al. gamma-Interferon-induced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses. J Clin Endocrinol Metab 1997, 82:2222-2232.
23. Dusso AS, Finch J, Brown A, Ritter C, Delmez J, Schreiner G, et al. Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab 1991, 72:157-164.
24. Strugnell S, Calverley MJ, Jones G. Metabolism of a cyclopropane-ring-containing analog of 1 alpha-hydroxyvitamin D3 in a hepatocyte cell model. Identification of 24-oxidized metabolites. Biochem Pharmacol 1990, 40:333-341.
25. Monkawa T, Yoshida T, Hayashi M, Saruta T. Identification of 25-hydroxyvitamin D3 1alpha-hydroxylase gene expression in macrophages. Kidney Int 2000, 58:559-568.
26. Dusso A, Brown A, Slatopolsky E. Extrarenal production of calcitriol. Semin Nephrol 1994, 14:144-155.
27. Miossec P, Archambeaud-Mouveroux F, Teissier MP. [Inhibition of steroidogenesis by ketoconazole. Therapeutic uses]. Ann Endocrinol (Paris) 1997, 58:494-502.
28. Glass AR, Eil C. Ketoconazole-induced reduction in serum 1,25-dihydroxyvitamin D. J Clin Endocrinol Metab 1986, 63: 766-769.
29. Glass AR, Eil C. Ketoconazole-induced reduction in serum 1,25 dihydroxyvitamin D and total serum calcium in hypercalcemic patients. J Clin Endocrinol Metab 1988, 66:934-938.
30. Glass AR. Ketoconazole-induced stimulation of gonadotropin output in men: basis for a potential test of gonadotropin reserve. J Clin Endocrinol Metab 1986, 63:1121-1125.
31. Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Storozhuk E, et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 1998, 26:552-561.
32. Koeplinger KA, Raub TJ, Padbury GE, Zhao Z. Equilibrium distribution of HIV antiviral drugs into human peripheral blood mononuclear cells (PBMC) is controlled by free drug concentration in the extracellular medium. J Pharm Biomed Anal 1999, 19:399-411.
33. Tebas PYK, Whyte M, Claxton S, DeMarco D, Powderly W. Serum an d urine markers of bone mineral metabolism in HIV infected patients taking protease inhibitor containing potent antiretroviral therapy. Antiviral Therapy Second International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Toronto, September 2000.
34. Tanaka S, Haji M, Takayanagi R, Sugioka Y, Nawata H. 1,25-Dihydroxyvitamin D3 enhances the enzymatic activity and expression of the messenger ribonucleic acid for aromatase cytochrome P450 synergistically with dexamethasone depending on the vitamin D receptor level in cultured human osteoblasts. Endocrinology 1996, 137:1860-1869.
35. Kinuta K, Tanaka H, Moriwake T, Aya K, Kato S, Seino Y. Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads. Endocrinology 2000, 141:1317-1324.
36. Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Watkins PB. Induction of CYP3A4 by 1 alpha,25-dihydroxyvitamin D3 is human cell line-specific and is unlikely to involve pregnane X receptor. Drug Metab Dispos 2001, 29:1446-1453.
37. Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Lown KS, Watkins PB. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. Mol Pharmacol 1997, 51:741-754.